AIM: To select the proper excipients for granule of compound Saliva Miltiorrhiza and the preparative process. METHODS: Building up properties, solubility and resistance to humid were used as the judgement criteria, the kinds and ratio of the excipients and preparative process sieved out. RESULTS: Properere excipent combination consisted of one portion of the extract of compound Salvia Miltiorrhiza, 1.6 times dextin, 2.6% CMC Na, 1% PVP, 2.6% CMS Na. CONCLUSION: The process and its excipent combination is better than the other process of formulation.

[Objective]Modify Xuejiejiawei Granule judgment toxic particles to guide its clinical drug safety.[Method]Make different dosages,give the mouse to fill stomach,from the observing mouse's physiological condition to judging the medicine toxic.[Result]36 mice after given the medicine observation period do not have an example to die,after the dissection the internal organs have non-pathological changes.[Conclusion] Looking at Xuejiejiawei Granule from the medicine toxic effect,the Xuejie adding the taste pellet is a safe medicine.

Nanometer zinc oxide (Nano-ZnO) has been widely applied in many fields such as rubber,ceramics,textile,cosmetics,etc.due to its excellent physical,chemical and biological properties.In recent years,its applications in biomedicine have been paid more and more attention.This paper introduces the unique optical,chemical,mechanical,semi-conducting and biological properties of Nano-ZnO.Meanwhile,the applications of Nano-ZnO in bio-sensing and detection,biological nutrition,medical treatment,biological imaging,drug delivery,tumor cells targeted killing and translational medicine are also reviewed,and the brief outlook on the applications is presented.

Objective: To explore the quality of life and drug toxicity in NSCLC (non-small cell lung cancer) patients who have a ECOC (Eastern Cooperative Oncology Group)-PS (performance status) score ≥3 and a response to gefitinib more than 6 months, and to explore the possibily of gefitinib applying in NSCLC patients with a ECOG-PS score ≥3. Methods: NSCLC patients histologically and (or) cytologically confirmed were divided into trial group (ECOG-PS score ≥3) and control group (ECOG-PS score ≤2). The patients in the two groups were treated with a dose of 250 mg/d gefitinib. The efficacy, change of quality of life and the toxicity were evaluated. Results: Eighty-eight NSCLC patients were enrolled in this study (trial group: n = 27; control group: n = 61). The median follow-up time was 20.0 months. All patients in the two groups could be évaluable. In the trial group, 4 (14.81%) patients obtained CR (complete response), 20 (74.07%) patients obtained PR (partial response), 3 (11.11%) patients obtained SD (stable disease); the response rate was 88.89% (24/27). In the control group, 10 (16.39%) patients obtained CR (complete response), 43 (70.49%) patients obtained PR (partial response), 8 (13.11%) patients obtained SD (stable disease); the response rate was 86.89% (53/61). There was no difference in response rate between the two groups (P = 0.794). The median time to symptom improvement of the trial group and the control group were 10.0 and 14.0 d, respectively (P = 0.073), the median PFS (progression-free survival) were 8.0 and 7.0 momths, respectively (P = 0.421). The 1-, 2- and 3-year survival rates were 59.269% (16/27), 25.93% (7/27) and 3.70% (1/27) in the trial group and 57.38% (35/61), 21.31% (13/61) and 6.56% (4/61), respectively. There was no difference in survival rate between the two groups (P = 0.180). The ECOG-PS score after gefitinib therapy (vs before gefitinib therapy) was significantly decreased in the two groups (Trial group Z = -4.062, P = 0.000; Control group Z = -4.031, P = 0.000), and the percent decrease of ECOG-PS score after gefitinib therapy in the trial group was significantly higher as compared with that in the control group. The toxicities of gefitinib therapy were tolerated. Conclusion: Gefitinib can be safely applied in NSCLC patients with ECOG-PS score ≥3. There is no difference in survival time between NSCLC patients with ECOG-PS score ≥3 and ≤2, but the quality of life in NSCLC patients with ECOG-PS score 2= 3 is significantly impoved as compard with NSCLC patients with ECOG-PS score ≤2 after gefitinib therapy. Copyright © 2013 by TUMOR.

Aged ; Humans ; Immunoglobulin M ; Liver Failure, Acute ; etiology ; Male ; Multiple Myeloma ; complications ; immunology

Objective To observe the efficacy of folic acid combined with mecobalamine for the treatment of vascular mild cogni-tive impairment (VMCI) in patients with cerebral small vessel disease (SVD) and hyperhomocysteinemia(Hcy) .Methods A total of 84 VMCI patients with cerebral small vessel disease and Hcy were randomly divided into combination group and control group . Two groups received conventional therapy for 6 months .Besides ,the combination group received folic acid combined with mecobal-amin .The level of plasma Hcy and ADAS-cog score were observed before and after 3 months and 6 months treatment .Results Af-ter treatment ,plasma Hcy significantly lower in the combination group (P<0 .01) ,whereas it did not show any improvement in the control group .ADAS-cog scores in combination group decreased compared with that of before treatment ,but there was no statisti-cally significant difference after 3 months treatment(P>0 .05) .However ,after 6 months treatment ,the ADAS-cog scores decreased obviously than that in the before treatment group (P<0 .05) .ADAS-cog scores in control group increased compared with before treatment ,but there was no statistically significant difference in after treatment (P>0 .05) .After 3 months treatment ,there was no significant difference on ADAS-cog score between combination group and control group (P>0 .05) ,however ,there had significant difference between the two groups after 6 months treatment(P<0 .05) .Conclusion The level of plasma Hcy could be reduced by adding folic acid and mecobalamin .Treatment of hyperhomocysteinemia may delay the progression of vascular cognitive impairment w hich caused by cerebral small vessel disease .

25) and in the group with complication of craniocerebral injury (P25) were significantly increased compared with other groups (P5) showed significunt difference as compared with that of with other groups (P

Objective To study the TCM syndrome distribution and characteristics of pregnant patients with cold in Panzhihua region;To provide evidence for prevention and treatment of this disease.Methods Totally 107 pregnant patients with cold were analyzed to obtain TCM syndrome data and summarize the distribution and characteristics of this disease.Results The syndromes of 107 cases of pregnancy cold, from high to low were sore throat (64.49%), thirst (62.62%), nasal congestion (61.68%), cough (59.81%), runny nose (55.15%), and defense phase symptoms such as sore throat, thirst and nasal congestion were obvious. The main TCM syndrome was wind-heat syndrome, accounting for 82.24%. The incidence rates of early pregnancy (<12weeks), midtrimester pregnancy (13-27 weeks), and late pregnancy (>28 weeks) were 32.71% (35/107), 44.86% (48/107), and 22.43% (24/107), respectively. The incidence rates of early pregnancy and midtrimester pregnancy were higher than that of late pregnancy (P<0.05). The incidence rates were 53.27% (57/107) in spring and summer and 46.73% (50/107) in autumn and winter, with statistical significance (P<0.01). The incidence of wind-heat syndrome in spring and summer was 62.5% (55/88),Conclusion The most common syndrome in pregnancy cold was wind-heat syndromes. The most common characteristics were warm, hot and dry. Early or middle pregnant patients were more likely to catch cold in spring and summer. The syndrome distribution and characteristics were relevant to local environment and climate factors.

Objective To isolate the anti-tumor protein groups from Pinellia ternata rhizome and investigate the anti-tumor activity of these protein groups on Bel-7402 cell. Methods The total raw protein was isolated with sepharose column chromatography. Methyl-thiazolyl-tetrazolinm (MTT) was used to analyze the effect of Pinellia ternata Protein on inhibiting growth of tumor cells. Apoptosis was detected by flow cytometry (FCM). Results The 30% and 60% (NH4)2SO4 deposition part of total proteins from Pinellia ternata rhizome have no certain relationship between quantity and inhibitory action, but protein peak 3 eluted with 0.05 mol/L or 0.1 mol/L NaCl from 30% (NH4)2SO4 deposition part showed a effect of concentration depending. FCM analysis showed that the protein of 30% (NH4)2SO4 deposition part could induce apoptosis. Conclusion The 30% (NH4)2SO4 deposition part of total proteins from Pinellia ternata rhizome could significantly inhibit Bel-7402 growth and induce its apoptosis.

Objective To evaluate the relationship between the cervical length,the test of fetal fibronectin and premature birth in pregnant woman.Methods Fetal fibronectin in sample of cervical secretion was tested using the reagent box of FFN manufactured by the ADEIA company of the United States and enzyme-labeled immunosorbent assay(ELISA) methods in 110 pregnant women.They were divided into two groups:first group,there were 60 cases who had symptom of aura prematurity and cervical lengths ≤30 mm monitored by trans-perineum ultrasound.second group was 50 normal pregnant women.Results The postive rate of fetal fibronectin was higher significantly in first group than that in second group.Conclusion The measurement of cervical lengths by the trans-perineum ultrasound and the test of Fetal fibronectin in pregnant women who has symptom of aura prematurity are of certain clinical value in predicting preterm birth.